[go: up one dir, main page]

AU3711900A - Method of increasing bone volume using non-naturally-occurring ep1 selective agonists - Google Patents

Method of increasing bone volume using non-naturally-occurring ep1 selective agonists Download PDF

Info

Publication number
AU3711900A
AU3711900A AU37119/00A AU3711900A AU3711900A AU 3711900 A AU3711900 A AU 3711900A AU 37119/00 A AU37119/00 A AU 37119/00A AU 3711900 A AU3711900 A AU 3711900A AU 3711900 A AU3711900 A AU 3711900A
Authority
AU
Australia
Prior art keywords
naturally
occurring
agonist
bone
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37119/00A
Other languages
English (en)
Inventor
Mitchell Anthony Delong
James Richard Hartke
Mark Walden Lundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU3711900A publication Critical patent/AU3711900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU37119/00A 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep1 selective agonists Abandoned AU3711900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05
US60123063 1999-03-05
PCT/US2000/005196 WO2000051585A2 (en) 1999-03-05 2000-03-01 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume

Publications (1)

Publication Number Publication Date
AU3711900A true AU3711900A (en) 2000-09-21

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37119/00A Abandoned AU3711900A (en) 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep1 selective agonists

Country Status (10)

Country Link
EP (1) EP1158969A2 (es)
JP (1) JP2002538105A (es)
AU (1) AU3711900A (es)
CA (1) CA2366755A1 (es)
CO (1) CO5150205A1 (es)
IL (1) IL145128A0 (es)
NO (1) NO20014192L (es)
NZ (1) NZ513828A (es)
PE (1) PE20001552A1 (es)
WO (1) WO2000051585A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118173A1 (ja) 2005-04-28 2006-11-09 Ono Pharmaceutical Co., Ltd. 経皮吸収製剤
EP2085088A4 (en) 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
US20110038884A1 (en) 2008-04-28 2011-02-17 National University Co., Hamamatsu Univer. School Of Medicine Immunopotentiating agent comprising ep1 agonist
EP2542263A4 (en) * 2010-03-05 2013-07-31 Univ Rochester EP1 INHIBITION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
AU2146592A (en) * 1991-05-29 1993-01-08 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
KR20010023840A (ko) * 1997-09-09 2001-03-26 데이비드 엠 모이어 비천연 선택성 ｆｐ 아고니스트를 이용한 골 부피 증가 방법
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
JP2002538105A (ja) 2002-11-12
EP1158969A2 (en) 2001-12-05
WO2000051585A3 (en) 2001-01-25
CA2366755A1 (en) 2000-09-08
PE20001552A1 (es) 2001-01-30
NO20014192D0 (no) 2001-08-29
IL145128A0 (en) 2002-06-30
WO2000051585A2 (en) 2000-09-08
NO20014192L (no) 2001-11-05
CO5150205A1 (es) 2002-04-29
NZ513828A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
US6156799A (en) Method of increasing bone volume using non-naturally-occurring FP selective agonists
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
CA1327003C (en) Pharmacological use of uridine in the treatment of nervous disorders
JPWO2003007991A1 (ja) Ｌｐａ受容体調節剤からなる膵液分泌制御剤
EP1140054B1 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU3711900A (en) Method of increasing bone volume using non-naturally-occurring ep1 selective agonists
US20030158247A1 (en) Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
AU9130298A (en) Method of increasing bone volume
CN1112920C (zh) 氨基四氢化萘衍生物在制备治疗心脏病的药物中用途
WO2000051616A1 (en) Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
KR20070085436A (ko) 진통제
MXPA00002395A (es) Metodo para incrementar el volumen oseo
MXPA00002394A (es) Metodo para incrementar el volumen oseo usando agonistas selectivos de prostanoide f no naturales
JP5039236B1 (ja) 抗不整脈剤及び心房細動抑制剤
CN1354676A (zh) 用于心血管疾病疗法的氨基四氢化萘衍生物
JPH1135470A (ja) ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
CZ2000808A3 (cs) Použití selektivního FP agonisty, který se přirozeně nevyskytuje
CN1202826C (zh) 神经障碍治疗剂
JP2002538122A (ja) 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
JP5615868B2 (ja) 持続性心房細動モデル及びその製造方法、並びに、心房細動抑制剤のスクリーニング方法
HK1020566A (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted